Literature DB >> 26355132

Clinical Needs of Patients with Problem Drug Use.

Antoinette Krupski1, Imara I West2, Meredith C Graves2, David C Atkins2, Charles Maynard2, Kristin Bumgardner2, Dennis Donovan2, Richard Ries2, Peter Roy-Byrne2.   

Abstract

INTRODUCTION: Illicit drug use is a serious public health problem associated with significant co-occurring medical disorders, mental disorders, and social problems. Yet most individuals with drug use disorders have never been treated, though they often seek medical treatment in primary care. The purpose of this study was to examine the baseline characteristics of people presenting in primary care with a range of problem drug use severity to identify their clinical needs.
METHODS: We examined sociodemographic characteristics, medical and psychiatric comorbidities, drug use severity, social and legal problems, and service utilization for 868 patients with drug problems. These patients were recruited from primary care clinics in a medical safety net setting. Based on Drug Abuse Screening Test results, individuals were categorized as having low, intermediate, or substantial/severe drug use severity.
RESULTS: Patients with substantial/severe drug use severity had serious drug use (opiates, stimulants, sedatives, intravenous drugs); high levels of homelessness (50%), psychiatric comorbidity (69%), and arrests for serious crimes (24%); and frequent use of expensive emergency department and inpatient hospitals. Patients with low drug use severity were primarily users of marijuana, with little reported use of other drugs, less psychiatric comorbidity, and more stable lifestyles. Patients with intermediate drug use severity fell in between the substantial/severe and low drug use severity subgroups on most variables.
CONCLUSIONS: Patients with the highest drug use severity are likely to require specialized psychiatric and substance abuse care, in addition to ongoing medical care that is equipped to address the consequences of severe/substantial drug use, including intravenous drug use. Because of their milder symptoms, patients with low drug use severity may benefit from a collaborative care model that integrates psychiatric and substance abuse care in the primary care setting. Patients with intermediate drug use severity may benefit from selective application of interventions suggested for patients with the highest and lowest drug use severity. Primary care safety net clinics are in a key position to serve patients with problem drug use by developing a range of responses that are locally effective and that may also inform national efforts to establish patient-centered medical homes and to implement the Affordable Care Act. © Copyright 2015 by the American Board of Family Medicine.

Entities:  

Keywords:  Comorbidity; Delivery of Health Care; Drug Abuse; Health Care Costs; Integrated; Primary Health Care

Mesh:

Year:  2015        PMID: 26355132      PMCID: PMC4883106          DOI: 10.3122/jabfm.2015.05.150004

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  24 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  Joint principles: Integrating behavioral health care into the patient-centered medical home.

Authors: 
Journal:  Fam Syst Health       Date:  2014-06       Impact factor: 1.950

3.  Joint principles: integrating behavioral health care into the patient-centered medical home.

Authors:  Mac Baird; Alexander Blount; Stacy Brungardt; Perry Dickinson; Allen Dietrich; Ted Epperly; Larry Green; Douglas Henley; Rodger Kessler; Neil Korsen; Susan McDaniel; Ben Miller; Perry Pugno; Richard Roberts; Julie Schirmer; Deb Seymour; Frank Degruy
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

4.  The drug abuse screening test.

Authors:  H A Skinner
Journal:  Addict Behav       Date:  1982       Impact factor: 3.913

5.  A meta-analysis comparing the effectiveness of buprenorphine and methadone.

Authors:  S L West; K K O'Neal; C W Graham
Journal:  J Subst Abuse       Date:  2000

6.  Brief intervention for problem drug use in safety-net primary care settings: a randomized clinical trial.

Authors:  Peter Roy-Byrne; Kristin Bumgardner; Antoinette Krupski; Chris Dunn; Richard Ries; Dennis Donovan; Imara I West; Charles Maynard; David C Atkins; Meredith C Graves; Jutta M Joesch; Gary A Zarkin
Journal:  JAMA       Date:  2014-08-06       Impact factor: 56.272

7.  Commitment to abstinence and acute stress in relapse to alcohol, opiates, and nicotine.

Authors:  S M Hall; B E Havassy; D A Wasserman
Journal:  J Consult Clin Psychol       Date:  1990-04

8.  Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: comparison with matched controls.

Authors:  Jennifer R Mertens; Yun W Lu; Sujaya Parthasarathy; Charles Moore; Constance M Weisner
Journal:  Arch Intern Med       Date:  2003-11-10

9.  Mental health, substance abuse, and health behavior services in patient-centered medical homes.

Authors:  Rodger Kessler; Benjamin F Miller; Mark Kelly; Debbie Graham; Amanda Kennedy; Benjamin Littenberg; Charles D MacLean; Constance van Eeghen; Sarah Hudson Scholle; Manasi Tirodkar; Suzanne Morton; Wilson D Pace
Journal:  J Am Board Fam Med       Date:  2014 Sep-Oct       Impact factor: 2.657

10.  Improving health-based payment for Medicaid beneficiaries: CDPS.

Authors:  R Kronick; T Gilmer; T Dreyfus; L Lee
Journal:  Health Care Financ Rev       Date:  2000
View more
  2 in total

1.  Health Services Use Among Jailed Women with Alcohol Use Disorders.

Authors:  Christine Timko; Jennifer E Johnson; Megan Kurth; Yael Chatav Schonbrun; Bradley J Anderson; Michael D Stein
Journal:  J Behav Health Serv Res       Date:  2019-01       Impact factor: 1.505

2.  Resource consumption of multi-substance users in the emergency room: A neglected patient group.

Authors:  Laurence Klenk; Christina von Rütte; Jonathan F Henssler; Thomas C Sauter; Wolf E Hautz; Aristomenis K Exadaktylos; Martin Müller
Journal:  PLoS One       Date:  2019-09-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.